Search Results for: Pharma: Other News to Note
-
Other News To Note
BioChem will continue to manufacture the drug at its Quebec facilities...The company plans to initiate a dose-escalating study in the second quarter that will evaluate the safety and feasibility of the stents to reduce restenosis. Calypte Biomedical Corp., of Alameda, Calif., said its founder and chief scientific officer, Howard Urnovitz, and its chairman, William Boeger, established a new company named Chronix Biomedical that will focus on novel ways to detect aberrant genes in individuals with -
Other News To Note
Sugen will retain exclusive, worldwide rights to commercialize products resulting from the collaboration, while Evotec will be entitled to royalties. Guilford Pharmaceuticals Inc., of Baltimore, said it acquired exclusive worldwide development and commercialization rights to a novel anesthetic compound developed by ProQuest Pharmaceuticals Inc., of Lawrence, Kansas -
Other News To Note
Patients continued to show favorable trends, with more than 95 percent of the patients remaining stable or improved after 12 treatments administered over a 16-month time span. Ariad Pharmaceuticals Inc., of Cambridge, Mass., said its gene-targeted drug, AP1903, was granted orphan drug status by the FDA for the treatment of acute graft-vs.-host disease. BioSignal Inc., of Montreal, said it completed the delivery of a 500,000 data-point screen to BASF Pharma, of Ludwigshafen, Germany -
Other News To Note
Alexion received exclusive worldwide rights to novel anti-inflammatory technologies and to associated therapeutic products expected to have broad application in patients with atherosclerosis, unstable angina, stroke and other vascular disorders. Alliance Pharmaceutical Corp., of San Diego, said preliminary efficacy results from three Phase II cardiac surgery trials with Oxygent, its intravascular oxygen carrier, showed that Oxygent eliminated or reduced the need for donor blood transfusions -
Other News To Note
The company expects to use net proceeds for FluMist regulatory filings, manufacturing and commercialization, and for the development of a second-generation formulation of FluMist. Cambridge Antibody Technology Group plc, of Melbourn, England, said BASF Pharma, of Ludwigshafen, Germany, initiated Phase III trials of the fully human anti-TNF monoclonal antibody D2E7 in rheumatoid arthritis...The entry into Phase III triggers a milestone payment from BASF Pharma to Cambridge Antibody. Hemispherx -
Other News To Note
The institute will have access to mice from Lexicon's OmniBank library of knockout mouse clones for use in determining the function of genes that represent potential drug targets...SemBioSys will supply the product to NADII, which will have exclusive rights to the product -
Other News To Note
Cell Genesys will receive royalties on worldwide sales of Clontech's research kits and any future products employing retroviral gene delivery technology. Hemispherx Biopharma Inc., of Philadelphia, said its wholly owned subsidiary, Hemispherx Biopharma Europe, has been awarded a research and development grant from Rhone-Poulenc Rorer SA, of Antony, France, which recently merged with Hoechst Marion Roussel AG, of Frankfurt, Germany, to become Aventis Pharma...Keryx intends to use the proceeds to -
Other News To Note
Early products could be a series of novel vaccines against cancer and other diseases. Incara Pharmaceuticals Corp., of Research Triangle Park, N.C., said its board authorized the initiation of a stock repurchase program whereby up to $2 million of the company's stock may be repurchased in the open market over the next two months. Inex Pharmaceuticals Corp., of Burnaby, British Columbia, signed an investment agreement with the federal government's Technology Partnerships Canada (TPC) under -
Other News To Note
The deals, with SmithKline Beecham, Kyowa Hakko Kogyo and Bayer Corp., relate to Phase Zero, Pharmagene's system for target identification and validation, and for testing drug leads in human tissue before they enter the clinic...Pharmagene said it now has 12 international pharmaceutical company clients. Supratek Pharma Inc., of Montreal, said it achieved gene expression comparable to that of viral vectors, without the associated safety concerns -
Other News To Note
Preclinical work on the in-licensed project and the company's other antibodies will be conducted at its research facility in Edmonton, Alberta. AntexBiologics, of Gaithersburg, Md., said its wholly owned subsidiary, Antex Pharma Inc., created a new class of compounds to fight antibiotic-resistant bacteria that are distinct from the currently marketed antibiotics...The milestone relates to ImClone's preparation and delivery of a regulatory document to Merck for its submission for a Phase II study -
Other News To Note
Cambridge NeuroScience has been granted a license under three Algos patents to develop products to treat pain, and Algos has gained the right to negotiate to develop and commercialize the products. Genzyme Tissue Repair, of Cambridge, Mass., said the $13 million convertible note issued in February 1997 has been fully converted by its private holder...The company has no further obligations under the note. Discovery Therapeutics Inc., of Richmond, Va., said it is expanding its 1998 -
Other News To Note
The payment is in addition to the recent $4.5 million payment for completion of a GVAX lung cancer study...Cell Genesys retained North American marketing rights in the potential $153 million deal. (See BioWorld Today, Dec. 21, 1999, p. 1.) Discovery Therapeutics Inc., of Richmond, Va., and Schwarz Pharma AG, of Monheim, Germany, expanded their 1998 collaboration, giving Schwarz rights in Japan to the Parkinson-Patch, a transdermal formulation of a dopamine agonist (DTI's N-0923...Oxis' stock -
Other News To Note
Some of the developers of the technology are transferring to Celera. GelTex Pharmaceuticals Inc., of Waltham, Mass., and Sankyo Pharma Inc., of Tokyo, signed the final agreements related to the licensing of GelTex's Cholestagel and an option on a second-generation cholesterol-lowering agent...The deal is worth up to $75 million. (See BioWorld Today, Nov. 16, 1999, p. 1.) Human Genome Sciences Inc., of Rockville, Md., said Credit Suisse First Boston, the purchaser in a private placement of -
Other News To Note
to act as its investment banker and financial adviser. Incyte Pharmaceuticals Inc., of Palo Alto, Calif., and University of Cambridge, UK, researchers said they confirmed, using SNP technology, a key gene responsible for Type II diabetes, severe insulin resistance and early onset hypertension...Alibra is designed to be effective within five to 10 minutes and last for 30 to 60 minutes -
Other News To Note
In preclinical studies, the drug indicated it was considerably more potent and less toxic than other antisense agents in clinical development. Cephalon Inc., of West Chester, Pa., and Schwarz Pharma AG, of Monheim, Germany, signed a licensing agreement to develop and market certain Cephalon compounds in Europe and several other territories outside the U.S...The purpose of the increase in authorized shares is to provide more flexibility for several possible transactions, including stock splits or -
Other News To Note
to support the preclinical development of these inhibitors through December 2000, resulting in additional payments to Corvas totaling $3 million. Human Genome Sciences Inc., of Rockville, Md., closed its private placement of $150 million principal amount of 5 percent convertible subordinated notes due 2006. (See BioWorld Today, Dec. 7, 1999, p. 2.) Incyte Pharmaceuticals Inc., of Palo Alto, Calif., and Oxford Gene Technology Ltd., of Oxford, UK, entered into a cross licensing agreement -
Other News To Note
To date, ImmunoGen has received $9.5 million in milestone payments. Isis Pharmaceuticals, of Carlsbad, Calif., started a Phase IIa study of a topical formulation of ISIS 2302 in psoriasis patients...Incyte will use GeneMatcher to develop databases for medical researchers. Photogen Technologies Inc., of Knoxville, Tenn., said Lucy Young, who is working under a research agreement with the company, presented findings showing complete eradication of ocular melanoma tumors in 84 percent of lab -
Other News To Note
NIHL also has the option to purchase an additional 30 percent interest for $6 million. Ciba Vision Corp., of Atlanta, signed a co-development agreement with Destiny Pharma, of Brighton, England, which grants Ciba exclusive global rights to develop Destiny's photodynamic therapy technology to treat ophthalmic diseases -
Other News To Note
The suit alleges investors were misled by a press release into thinking news about the company's cancer drug, Angiozyme, was going to be more significant than it entering Phase I/II testing...The stock doubled on the news, then fell back to its original price after further details were disclosed. Therion Biologics Corp., of Cambridge, Mass., said it was awarded three contracts totaling $1.5 million from the NIH's National Institute of Allergy and Infectious Disease for the development and -
Other News To Note
The Phase III trial is now being planned by CAT's partner, BASF Pharma. Oxford Biomedica, of Oxford, UK, has reported efficient transfer of genes to the brain using its proprietary LentiVector system in a preclinical model of Parkinson's disease...The LentiVector system, based on the equine infectious anemia virus, could be used for gene therapy in other neurodegenerative diseases and leukemias. Peptor Ltd., of Rehovot, Israel, said it plans to sell shares to the public in Europe early next
Category
Related Keywords
Categories
- x BioWorld Today (2131)
- x BioWorld International (487)
- x BioWorld Insight (45)
- x Bio Perspectives (27)
- x State of the Industry Report (5)
- x BioWorld Snapshots (1)